Microbot Medical INC

Microbot Medical Inc. announced significant second-quarter growth with over 100% revenue and customer increase, driven by the Full Market Release of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. has announced an addendum to its Chief Financial Officer's employment agreement, increasing her annual base salary.

Microbot Medical Inc. announced its CEO will present on endovascular robotics at the Society of Robotic Surgery annual meeting.

Microbot Medical Inc. announced over 100% revenue and new customer growth in Q2 2026, driven by the LIBERTY System's full market release and expanding sales territories.

Microbot Medical Inc. has entered into a strategic agreement with Sanmina Corporation to enhance manufacturing capacity for its LIBERTY Endovascular Robotic System, aiming to meet growing demand and reduce costs.

Microbot Medical received the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. announced its Q2 2026 financial results, showing initial revenues from its LIBERTY Endovascular Robotic System following its full market release.

Microbot Medical reports Q1 2026 revenue of $105,000 as it transitions from development to commercialization of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. reports significant capital raises and FDA 510(k) clearance for its LIBERTY Endovascular Robotic Surgical System, enhancing its financial position and market readiness.

Microbot Medical reports significant capital raises and increased liquidity to fund ongoing research and development for its robotic surgical systems, despite widening net losses.

Microbot Medical Inc. announces its financial results for the first quarter of 2025, highlighting advancements in its LIBERTY Endovascular Robotic Surgical System and recent capital raising activities.

Microbot Medical Inc. announces its third quarter 2024 financial results, highlighting progress in its LIBERTY Endovascular Robotic Surgical System development and clinical trial.

Microbot Medical Inc. reports FDA clearance for its LIBERTY Endovascular Robotic Surgical System and initiates limited market release, while continuing to incur significant operating losses and requiring additional funding.

Microbot Medical's 10-K filing highlights the company's continued operating losses, its strategic focus on the LIBERTY Endovascular Robotic Surgical System, and recent capital raising activities to support its operations.

Microbot Medical Inc. released its 2023 annual report, detailing financial results and progress on its LIBERTY robotic surgical system.

Rachel Vaknin, CFO of Microbot Medical Inc., reports the acquisition of stock options and the vesting of performance-based options.

Harel Gadot, CEO of Microbot Medical Inc., reports the acquisition of stock options and the vesting of performance-based options.

Sharon Simon, General Manager and CTO of Microbot Medical Inc., reports the acquisition of stock options.

Juan Diaz-Cartelle, Chief Medical Officer of Microbot Medical Inc., reports the acquisition of stock options and the vesting of performance-based options.

Martin J. Madden, a director of Microbot Medical Inc., reports the acquisition of stock options.

Scott R. Burell, a director of Microbot Medical Inc., acquired stock options exercisable for 10,000 shares on January 28, 2025.

Microbot Medical Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Microbot Medical is asking shareholders to vote on several proposals at its 2025 Annual Meeting, including director elections, executive compensation, and an increase in authorized shares.

Microbot Medical Inc. has filed a definitive proxy statement with the SEC.

Microbot Medical is holding a special meeting to seek stockholder approval for issuing shares related to a recent offering and to increase the number of authorized shares of common stock.

Microbot Medical Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Microbot Medical Inc. has scheduled its 2024 Annual Meeting of Shareholders for December 17, 2024, to address director elections, an amendment to the company's performance award plan, and the ratification of its independent accounting firm.

Microbot Medical Inc. files an amendment to its Form S-1 registration statement with the SEC, indicating a continuous offering of securities.

Microbot Medical is registering for the resale of up to 15.9 million shares of its common stock, which are issuable upon the exercise of outstanding preferred investment options held by selling stockholders.

Microbot Medical has filed an amendment to its S-1 registration statement, covering the resale of up to 3,211,671 shares of common stock by selling stockholders upon exercise of preferred investment options.

Microbot Medical is registering for the resale of up to 3.2 million shares of its common stock, issuable upon the exercise of outstanding preferred investment options held by selling stockholders.

Microbot Medical has filed an amendment to its Form S-1 registration statement, pertaining to the resale of up to 1,005,965 shares of its common stock by selling stockholders, primarily related to the settlement of a lawsuit.

Microbot Medical is registering the resale of 1,005,965 shares of its common stock by selling stockholders following a settlement agreement.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 8.2% in Microbot Medical Inc. common stock.

Intracoastal Capital LLC and its affiliates have reported a 0% beneficial ownership in Microbot Medical Inc. common stock, excluding a warrant exercisable in March 2026.

The Vanguard Group has reported a reduced beneficial ownership in Microbot Medical Inc., now holding 4.45% of common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Microbot Medical Inc. as of June 30, 2025.

The Vanguard Group has reported a beneficial ownership of 5.63% in Microbot Medical Inc.'s common stock as of June 30, 2025.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 4.9% in Microbot Medical Inc., totaling 1,824,807 shares.